DEF: NKGen Biotech Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

NKGen Biotech is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and potentially improve stock marketability.

Summary

• NKGen Biotech is holding a special meeting on February 25, 2025, to seek stockholder approval for a reverse stock split.
• The proposed reverse stock split would allow the Board of Directors to combine outstanding shares at a ratio between 1-for-2 and 1-for-20.
• The exact ratio will be determined by the Board within twelve months of stockholder approval.
• The primary reason for the reverse stock split is to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The company received a deficiency letter from Nasdaq on September 23, 2024, and has until March 24, 2025, to regain compliance.
• The company's stock closed at $0.487 on January 30, 2025.
• The reverse stock split is also intended to improve the marketability and liquidity of the company's stock.
• The company is also seeking authorization to adjourn the special meeting if necessary to solicit additional proxies.

Sentiment

Score: 4

Explanation: The document indicates a need for a reverse stock split to avoid delisting, which is generally a negative sign. However, the company is taking proactive steps to address the issue, which is a positive.

Positives

• The reverse stock split could help the company regain compliance with Nasdaq listing requirements.
• A higher stock price may improve the marketability and liquidity of the company's shares.
• The reverse stock split could increase interest from institutional investors and analysts.
• Maintaining a Nasdaq listing can help attract, retain, and motivate employees and board members.
• The reverse stock split will help the company maintain compliance with its obligations under certain financing arrangements.

Negatives

• The reverse stock split may not result in a sustained increase in the stock price.
• The reverse stock split could decrease the liquidity of the company's stock.
• The reverse stock split may lead to a decrease in the company's overall market capitalization.
• Some stockholders may end up with odd lots of shares, which can be more difficult to sell.
• The reverse stock split will increase the number of shares available for issuance, which could dilute existing shareholders.

Risks

• The reverse stock split may not achieve the desired increase in stock price.
• The company may still be delisted from Nasdaq if it does not meet the minimum bid price requirement.
• The reverse stock split could lead to decreased liquidity and market capitalization.
• The company may face challenges in raising new equity capital in the future.
• The company may not be able to maintain compliance with its financing arrangements.

Future Outlook

The company intends to actively monitor the closing bid price for its common stock and will consider available options to resolve the deficiency and regain compliance with Rule 5450(a)(1). The Board will determine whether to implement the reverse stock split based on its assessment of the company's ability to maintain a stock price of at least $1.00 per share.

Management Comments

• The Board believes that it is prudent to seek stockholder approval for the Reverse Stock Split for the purpose of remaining in compliance with the Bid Price Rule.
• The Board believes that the increased market price of our common stock expected as a result of implementing a Reverse Stock Split could improve the marketability and liquidity of our common stock and encourage interest and trading in our common stock.

Industry Context

Many biotech companies face challenges in maintaining stock prices above minimum listing requirements, especially during periods of market volatility. Reverse stock splits are a common tool used by companies to address these issues and maintain their listing status on major exchanges.

Comparison to Industry Standards

• Reverse stock splits are a common practice for companies facing delisting from major exchanges like Nasdaq.
• Many companies in the biotech sector, particularly those in early stages of development, have used reverse stock splits to maintain compliance with listing requirements.
• The proposed range of 1-for-2 to 1-for-20 is within the typical range for reverse stock splits.
• Companies like Cassava Sciences and Ocugen have recently undergone reverse stock splits to maintain their Nasdaq listings.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own, but their percentage ownership will remain the same, except for fractional shares.
• Employees and directors who hold equity-based securities may be affected by the reverse stock split and the company's listing status.
• The company's ability to raise capital and maintain financing arrangements could be impacted by the reverse stock split and its listing status.

Next Steps

• Stockholders will vote on the reverse stock split proposal at the special meeting on February 25, 2025.
• The Board will determine the exact reverse stock split ratio within the approved range if the proposal is approved.
• The company will file a Certificate of Amendment with the Secretary of State of Delaware to effect the reverse stock split if approved by the board.
• The company will continue to monitor its stock price and consider other options to regain compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, stock listing, share price, stockholder meeting, proxy, compliance, marketability, liquidity